Luxeptinib effectively blocks the phosphorylation of AKT, ERK1/2, Plcg2, BTK, and S6 ribosomal proteins and significantly suppresses SYK phosphorylation in primary CLL cells [53]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.